C5aR2 in Breast Cancer and Its Relationship with Clinicopathological Features

Area of Science:

• Oncology
• Immunology

Background:

• Breast cancer is a significant global health concern.
• C5aR2 (Complement component 5a receptor 2) is a receptor implicated in inflammatory processes.
• Understanding the role of C5aR2 in breast cancer progression is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the correlation between C5aR2 expression and various clinicopathological parameters in breast cancer patients.
• To determine if C5aR2 expression levels can serve as a prognostic marker in breast cancer.

Main Methods:

• An observational study was conducted involving 128 women diagnosed with breast cancer.
• Immunohistochemistry (IHC) was utilized to assess C5aR2 expression in tumor and stromal cells, evaluating both percentage and intensity.
• Statistical analysis using SPSS version 27 correlated C5aR2 expression (via Immunoreactive Score - IRS) with clinicopathological features.

Main Results:

• C5aR2 expression was detected in 90.6% of tumor cells and 53.1% of stromal cells, primarily with cytoplasmic localization.
• Higher C5aR2 expression correlated with older age groups, higher tumor grade, and positive ER/PR/HER2 and HER2 statuses.
• Tumors with poor treatment response exhibited increased C5aR2 expression compared to those with good response, and elevated expression was noted in tumors with high cell proliferation rates, despite no significant association with Ki67.

Conclusions:

• Tumor and stromal C5aR2 expression is associated with key clinicopathological factors in breast cancer, including age, grade, receptor status, proliferation rate, and post-treatment response.
• These findings suggest that C5aR2 may play a role in breast cancer progression and could potentially be a prognostic indicator.